Registry data collection on patients with gastrointestinal stromal tumors in Taiwan
The Observational Registry: Nationwide Data Collection on Gastrointestinal Stromal Tumors (GISTs) Patients (Taiwan GISTs Registry)
This study is gathering information from patients with gastrointestinal stromal tumors in Taiwan to see how common the condition is, what treatments are being used, and how well those treatments are working.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | National Health Research Institutes, Taiwan Academic / other |
| Locations | 1 site (Taipei) |
| Trial ID | NCT03602092 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather and analyze real-world data on patients diagnosed with gastrointestinal stromal tumors (GIST) in Taiwan. It will collect information on the prevalence, demographic characteristics, treatment patterns, biomarker profiles, and treatment outcomes of GIST therapies, particularly focusing on tyrosine kinase inhibitors (TKIs). The study will utilize both retrospective and prospective data collection methods from medical records and a dedicated data bank, involving up to 3,000 eligible subjects. The findings will help assess nationwide trends in GIST diagnosis, treatment, and outcomes over a decade.
Who should consider this trial
Good fit: Ideal candidates for this study are Taiwanese patients aged 20 and older who have been histologically confirmed to have GIST between January 2010 and December 2020.
Not a fit: Patients who are unable or unwilling to provide informed consent or those unlikely to have long-term follow-up due to severe concomitant illnesses may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the management and treatment outcomes of GIST, potentially improving patient care and treatment strategies.
How similar studies have performed: While this study is observational and focuses on real-world data, similar studies have shown success in understanding treatment patterns and outcomes in other cancer populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed with Gastrointestinal Stromal Tumor 2. ≥20 years old 3. Histology-confirmed GIST between 01 January 2010 and 31 December 2020. 4. Patient with prospective data collection: Willing to provide singed inform-consent as per local regulatory requirements. Exclusion Criteria: 1. Inability and unwillingness to give informed consent if required by site ethic committee. 2. Patient that is unlikely candidate to obtain long-term follow-up information for reasons of unavailability or with severe concomitant illnesses per investigator judgement
Where this trial is running
Taipei
- Yu wei-lan — Taipei, Taiwan (Recruiting)
Study contacts
- Study coordinator: Hui-Jen Tsai, M.D
- Email: hjtsai@nhri.org.tw
- Phone: 886-06-2083427
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.